Skip to search formSkip to main contentSkip to account menu

Azedra

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long…
Abstract Background: Pheochromocytoma/Paraganglioma (PPGL) are rare neuroendocrine tumors with a 5-yr survival rate as low as 12… 
2020
2020
SAT-163 Status at 10 Years: Long-Term Follow-Up for a Phase 2a Study of High-Specific-Activity (HSA) I 131 Iobenguane in Patients (Pts) with Relapsed/Refractory High-Risk Neuroblastoma
Abstract Background: Metaiodobenzylguanidine (MIBG; iobenguane), a guanethidine derivative, is a substrate for norepinephrine… 
2020
2020
PD31-06 UPDATED LONG-TERM SURVIVAL AND SAFETY FROM A MULTI-CENTER, OPEN-LABEL, PIVOTAL PHASE 2 STUDY OF AZEDRA® IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR…
2019
2019
SUN-345 Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA®) in Patients with Iobenguane Scan Positive Cancers
Abstract Introduction: Iobenguane scan positive cancers including pheochromocytoma/paraganglioma (PPGL), neuroblastoma, and… 
2019
2019
Pooled safety analysis of high-specific-activity I-131 MIBG in iobenguane scan positive cancer patients.
388 Background: Iobenguane scan positive cancers include pheochromocytoma and paraganglioma (PPGL), neuroblastoma, and… 
2018
2018
Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label…
4005Background: AZEDRA, a high-specific-activity iodine-131 meta-iodobenzylguanidine (HSA I-131 MIBG), has been developed for the… 
2018
2018
First edible cottonseed go-ahead
particles. But instead of yttrium-90, Lutathera uses lutetium-177, a lower energy isotope that avoids some of the collateral… 
2018
2018
FDA Approves AZEDRA Specified Use in Pheochromocytomas/Paragangliomas.
Review
2018
Review
2018
Xtandi for Non-Metastatic Castration-Resistant Prostate Cancer
  • 2018
  • Corpus ID: 53343691
NEW DRUG APPROVALS Azedra for Rare Adrenal Tumors The FDA has approved Azedra (iobenguane I 131, Progenics Pharmaceuticals… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)